RATIONALE: Nasal steroids are first-line treatment for chronic rhinosinusitis (CRS), with nasal polyps. Some physicians prescribe once-daily (QD) regimens and some twice-daily (BID). This literature review compares once-vs twice-daily dosing. METHODS: We reviewed select reasonably sized randomized controlled trials (RCTs) testing the efficacy of QD or BID nasal steroids vs placebo in reducing polyp burden. RESULTS: Six RCTs exposing a total of 1,712 patients to conventional nasal steroid sprays or placebo were identified. In addition, two RCTs using a novel exhalation delivery system with fluticasone (EDS-FLU) were identified (N5643). In four RCTs (N5142, 310, 354, 748), mean total bilateral polyp grade (polyp grade) was significantly reduced with BID nasal steroid vs placebo. In contrast, three RCTs (N's5104, 142, 310) found that polyp grade improvement was not significantly better with QD nasal steroid compared to placebo. Only one large RCT (N5354) showed significant reduction in polyp grade with QD treatment, while one additional very small RCT (N554) reported reduction in polyp volume with a nonstandard scale. Notably, efficacy with mometasone nasal spray using BID dosing was replicated in 2 independent registration studies, but not with QD dosing. Both RCTs with EDS-FLU (NAVIGATE I/II) studied BID showed significant symptom reduction of comparatively large magnitude and statistically significant polyp grade reduction vs placebo. CONCLUSIONS: Evidence suggests that twice-daily treatment with topical corticosteroid is likely to offer more reliable efficacy than oncedaily treatment for patients with moderate-to-severe CRS with nasal polyps.
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Nasal challenge with ketorolac: utility and safety in clinical practice Marta Sanchez-Jareño, MD Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain. RATIONALE: Nasal ketorolac challenge (NKC) has been proposed as a diagnosis test for patients with aspirin exacerbated respiratory disease (AERD) with predominantly nasal symptoms. The aim of this study is to evaluate the clinical outcome of NKC with 16.38mg in everyday clinical practice. METHODS: Adult patients with symptoms of AERD who underwent NKC at Hospital La Paz from 2009 to 2016 were included. NKC was performed by intranasal increasing doses of ketorolac every 30 minutes up to a maximum accumulated dose of 16.38 mg. Negative NKC was followed by oral challenge (OC). We collected data as clinical characteristics, baseline nasal examination, peak nasal inspiratory flow rates, forced expiratory volume in 1 second (FEV1), blood eosinophils baseline levels and IgE levels. Data were analyzed with SAS 9.3 (SAS, Institute, Cary, NC, USA). RESULTS: NKC was performed in 19 patients (mean age 45 6 15 years), 10 were males. Six NKC were negative (32%). Five patients experienced rhinitis, 4 bronchial symptoms (decrease FEV1 > _ 15%) and 3 anaphylaxis occurred (2 with 16.38mg and 1 with 8,82mg). No significant differences were found between these 3 patients and the other 10 patients with a positive PNK. Negative PNK were followed by OC: 4 resulted negative, 1 showed bronchial symptoms and 1 urticaria. PNK with 16.38mg showed a sensitivity of 87%, specificity and positive predictive value of 100% and negative predictive value of 67%. CONCLUSIONS: NKC with 16.38mg is a useful method for diagnosis of AERD although it is not as safe in everyday clinical practice as previous publications. Vanderbilt University, Division of Allergy, Pulmonary and Critical Care Medicine, Nashville, TN. RATIONALE: Aspirin desensitization and initiation of high-dose aspirin is an effective means of controlling symptoms in patients with aspirinexacerbated respiratory disease (AERD). In practice, desensitization is often performed after sinus surgery, although the benefit of this has not been proven. We hypothesized that sinus surgery prior to aspirin desensitization would be associated with less severe aspirin-induced lower respiratory reactions during desensitization. METHODS: In this retrospective case series, adult subjects with AERD were identified who had undergone two aspirin desensitizations at Brigham and Women's Hospital, one within 60 days after sinus surgery and one in the absence of recent surgery. Subjects with incomplete spirometry data or whose desensitizations were aborted due to nonmedical reasons were excluded. Spirometry data were compared, and paired student's T-tests were used for analysis. Pretreatment with montelukast was controlled for by subgroup analysis. RESULTS: Fifteen subjects met inclusion criteria. Recent sinus surgery within 60 days was associated with significantly reduced decline in FEV1 during aspirin desensitization (mean FEV1 decrease of 0.28 L/min vs 0.50 L/min, p50.014, n515). Five of the 15 subjects (33%) who had significant aspirin-induced decrease in FEV1 prior to surgery (FEV1 decrease >15%) had no lower airway reaction during aspirin desensitization after sinus surgery (FEV1 decrease <15%). When subjects on montelukast postoperatively but not nonoperatively were excluded, a similar trend was observed but was less significant (mean FEV1 decrease of 0.35L/min vs 0.56 L/min, p50.057, n511). CONCLUSIONS: In patients with AERD, aspirin desensitization following a recent sinus surgery is associated with decreased aspirininduced lower airway reactivity and improved safety.
